Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer

* Breast cancer is histologically divided into non-invasive (approximately 10%) and invasive (approximately 90%), with invasive cancer being the target of chemotherapy. Invasive carcinoma is classified into four subtypes according to the expression levels of hormone receptor (HR) and human epidermal growth factor receptor type 2 (HER2). Among them, triple negative breast cancer accounts for 10% of invasive cancers and is the subtype with the poorest prognosis. * For triple negative breast cancer that is operable, chemotherapy with pembrolizumab is administered either preoperatively or postoper

Trial Details

NCT ID
NCT06976944
Phase
PHASE2
Sponsor
Yukinori Ozaki
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Pembrolizumab
  • Paclitaxel
  • Bevacizumab
Locations (sample)
  • Nagoya, Aichi-ken, Japan|35.18147,136.90641
  • Nagoya, Aichi-ken, Japan|35.18147,136.90641
  • Nagoya, Aichi-ken, Japan|35.18147,136.90641
  • Akita, Akita, Japan|39.71667,140.11667
  • Kashiwa-shi, Chiba, Japan

Key Eligibility Criteria

  • Male/female participants who are 18 years of age or older on the day of signing informed consent with histologically or cytologically confirmed dia…
  • Participants have been confirmed to be ER negative, HER2 negative according to the latest ASCO/CAP criteria. However, it does not matter whether th…
  • Participants have been confirmed to be PD-L1 positive in each site's evaluation using biopsy specimen or surgical specimen.
  • Participants who have not undergone chemotherapy for recurrent breast cancer. However, prior treatment of Olaparib for metastatic recurrence or unr…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →